SCM
BIO icon

Sterling Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Sterling Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Sell
546
-75
-12% -$21.3K ﹤0.01% 1277
2026
Q1 		$173K Sell
621
-474
-43% -$137K ﹤0.01% 1230
2025
Q4 		$332K Sell
1,095
-62
-5% -$19.3K 0.01% 1145
2025
Q3 		$324K Sell
1,157
-126
-10% -$34.3K ﹤0.01% 1166
2025
Q2 		$310K Buy
1,283
+225
+21% +$53.2K ﹤0.01% 1150
2025
Q1 		$258K Sell
1,058
-86
-8% -$25.9K ﹤0.01% 1144
2024
Q4 		$376K Buy
1,144
+408
+55% +$138K 0.01% 1075
2024
Q3 		$246K Buy
+736
New +$234K ﹤0.01% 1207
2016
Q4 		– Sell
-1,907
Closed -$312K – 954
2016
Q3 		$312K Buy
+1,907
New +$289K ﹤0.01% 802

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Sterling Capital Management's BIO Position: Q2 2026 in Review

Sterling Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 12% in Q2 2026, selling an estimated $21.3K and leaving 546 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1277.

Sterling Capital Management first reported a position in BIO in Q3 2016 and has held it in 9 quarters since. The position peaked at $376K in Q4 2024. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Sterling Capital Management held 546 shares of Bio-Rad Laboratories Class A worth $160K as of Q2 2026.
  • Sterling Capital Management sold 75 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $21.3K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1277 holding.
  • Sterling Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and has held it in 9 quarters since.
  • Sterling Capital Management's Bio-Rad Laboratories Class A position peaked at $376K in Q4 2024.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.